Last quarter (Q3 2023), SAB Biotherapeutics's total revenue was $1.27M, an increase of Infinity% from the same quarter last year. In Q3, SAB Biotherapeutics's net income was $-5.10M. See SAB Biotherapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 1.93M	$ 23.90M	$ 60.88M	$ 0.00	$ 3.44M
Cost of Revenue	-	-	-	-	-
Gross Profit	$ 1.93M	$ 23.90M	$ 60.88M	-	-
Operating Expense	$ 13.03M	$ 52.82M	$ 74.27M	$ -20.56M	$ 12.12M
Operating Income	$ -11.10M	$ -28.92M	$ -13.39M	$ 20.56M	$ -8.67M
Net Non Operating Interest Income Expense	$ -194.25K	$ -230.51K	$ -271.34K	$ -443.02K	$ -315.34K
Other Income Expense	$ 67.80K	$ -10.43M	$ 3.48M	$ 4.00K	$ 2.59K
Pretax Income	$ -27.19M	$ -18.72M	$ -17.14M	$ 20.12M	$ -8.99M
Tax Provision	$ 25.63K	$ 25.63K	$ -1.03M	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -11.25M	$ -18.74M	$ -17.14M	$ 20.12M	$ -8.99M
Basic EPS	$ -0.39	$ -0.43	$ -0.63	$ 0.46	$ -0.21
Diluted EPS	$ -0.39	$ -0.43	$ 0.00	$ 0.46	$ -0.21
Basic Average Shares	$ 153.22M	$ 43.52M	$ 27.34M	$ 43.47M	$ 43.47M
Diluted Average Shares	$ 153.22M	$ 43.52M	$ 0.00	$ 43.47M	$ 43.47M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 13.03M	$ 52.82M	$ 74.27M	$ -20.56M	$ 12.12M
Net Income From Continuing And Discontinued Operation	$ -27.21M	$ -18.74M	$ -17.14M	$ 20.12M	$ -8.99M
Normalized Income	$ -17.36M	$ -14.80M	-	$ 20.12M	$ -8.99M
Interest Expense	$ 87.70K	-	-	$ 469.15K	$ 428.48K
EBIT	$ -26.92M	$ -18.71M	$ -16.87M	$ 20.59M	$ -8.56M
EBITDA	$ -19.15M	$ -15.42M	$ -16.87M	$ 21.14M	$ -8.23M

Currency in USD

SAB Biotherapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing